Analysis: Breaking patents for vaccines would have little impact in Brazil and could pose challenges

For government and national laboratory authorities, such a strategy may be detrimental.

RIO DE JANEIRO, BRAZIL - Government and domestic private laboratory authorities involved in the production of vaccines against Covid-19 agree that the strategy to break patents of immunizers and medicines would have little impact on vaccination in the country. The alignment was expressed yesterday in a virtual public hearing held by the Senate.

The possible overturning of patents has provoked a clash between senators this week. Yesterday, the government and health sector technicians invited by the Temporary Commission of Covid-19 said that the country might not take advantage of the measure for not having a solid industrial base in . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?